This article is more than 5 years old. Information may no longer be current.

Intacs removal does not affect BCVA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — Removal of Intacs implants appears to be safe, according to data from the U.S. trials of the device.

Of the total of 684 eyes implanted with Intacs (Addition Technology) during Food and Drug Administration studies, 46 eyes had the refractive implants removed. Removal was not associated with a loss of more than two lines of best corrected visual acuity or induction of more than 1 D of astigmatism or myopia, researchers said. A return to preoperative values was seen in most cases.

Researchers here and elsewhere analyzed data from 41 eyes that had undergone Intacs removal and had reached the 3-month post-removal date. Of these eyes, 73% returned to within 0.5 D and 97% returned to within 1 D of baseline spherical equivalent. All patients returned to within 1 D of preoperative astigmatism values, and 88% returned to within 0.5 D. No patient lost more than two lines of BCVA.

The study is published in the August issue of Ophthalmology.